Select: All | None
Select: All | None
Select: All | None

RECOMBINANT RNA-DEPENDENT RNA POLYMERASE OF RNA VIRUSES

GÖTTE, Matthias, University of Alberta

The present disclosure provides nucleic acids, expression vectors, host cells for producing recombinant viral RNA-dependent RNA polymerase (RdRp) polypeptides of viruses such as Ebola virus. The present disclosure also provides methods and substrates for assaying activity of a RdRp polypeptide or a RdRp complex. Also provided herein are inhibitors of RdRp polypeptides of viruses such as Ebola virus for use in treating or preventing viral infection.

OLIGOSACCHARIDE CONJUGATES AND METHODS OF USE

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS, University of Alberta

There is provided a method of detecting in a sample the presence of an anti-M and/or anti-A and/or anti-C/Y antibody, the method comprising contacting the sample with a diagnostic conjugate provided according to the invention, comprising an oligosaccharide which comprises at least two units of 4,6-dideoxy-4-acylamido-a- pyranose and comprising at least one -(1-3)-link between adjacent 4,6-dideoxy-4-acylamido-a-pyranose units, in which the carbon at position 5 in the pyranose is linked to an...

MACROCYCLIC LACTONE RESISTANCE MARKER FOR DIROFILARIA IMMITIS

McGill University, Novartis Pharmaceuticals

The invention relates to a method for determining the responsiveness of a Dirofilaria spp. nematode to a macrocyclic lactone, by determining the genotype of the nematode at a position in a P-glycoprotein gene of the nematode corresponding to position 1 1, and optionally to position 618, in SEQ ID NO: 1, wherein the genotype GG at a position corresponding to position 1 1, or at positions corresponding to positions 1 1 and 618, in SEQ ID NO: 1 indicates that the nematode is likely resistant to...

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

University Health Network

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

CULTURE MEDIUM FOR MYOBLASTS, PRECURSORS THEREOF AND DERIVATIVES THEREOF

Laval University

This application relates to a serum-free culture medium that enables the proliferation of cell of the myogenic lineage while maintaining their ability to differentiate into functional muscle cells. Also contemplated herewith are method of culturing cells of the myogenic lineages and uses of the cultured cells for the treatment or the alleviation of symptoms of a muscular deficiencies.

FLUORO-CHLORO BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE

British Columbia Cancer Agency, University of British Columbia

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein, and wherein at least one of R1, R2, R3, R4 or R5 is F, are provided. Uses of such compounds for treatment of various indications, inciuding prostate cancer as well as methods of treatment involving such compounds are also provided.

PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY

University Health Network

The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.

HPK1 INHIBITORS AND METHODS OF USING SAME

University Health Network

Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as...

COMPOUND, COMPOSITION, AND METHODS FOR TREATING, PREVENTING, REDUCING, OR DELAYING ONSET OF OSTEOSARCOMA LUNG METASTASIS IN A SUBJECT

University of Calgary

Described herein is a method for treating, preventing, reducing, or delaying onset of, osteosarcoma lung metastasis in a subject, comprising: administering a therapeutically or prophylactically effective amount of a PPARγ agonist, an anti- inflammatory agent, or a neutrophil depleting agent, to a subject having or suspected of having osteosarcoma.

COMPOUNDS FOR TARGETING THYROID HORMONE RECEPTOR ALPHA ISOFORMS AND METHODS OF USE THEREOF

McMaster University

Two isoforms of thyroid receptor alpha (THRα1 and THRα2) have been found to be associated with the growth of cancer. Use of inhibitors of THRα1 (Formula I) and/or agonists of THRα2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THRα1 and THRaα2 in a tissue sample.